Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia

Antiviral Therapy

Volumn 12, Issue 2, 2007, Pages 253-260

  Ellis, Jane C ^a   L'homme, Rafaëlla F A ^b   Ewings, Fiona M ^c   Mulenga, Veronica ^d   Bell, Frank ^a   Chileshe, Regina ^d   Molyneux, Elizabeth ^a   Abernethy, Julia ^c   Van Oosterhout, Joep J G ^a   Chintu, Chifumbe ^d   Walker, A Sarah ^c   Gibb, Diana M ^c   Burger, David M ^b  

^a UNIVERSITY OF MALAWI   (Malawi)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d UNIVERSITY TEACHING HOSPITAL   (Zambia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; COTRIMOXAZOLE; ISONIAZID; LAMIVIR S; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BODY HEIGHT; BODY MASS; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE ESCALATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALAWI; MALE; OUTPATIENT; PREDICTOR VARIABLE; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; STEADY STATE; TABLET; ZAMBIA;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG COMBINATIONS; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; INFANT; LAMIVUDINE; MALAWI; MALE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; TABLETS; TREATMENT OUTCOME; ZAMBIA;

EID: 34147190912     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. WHO. Progress on global access to HIV antiretroviral therapy. An update on '3 by 5'. June 2005. Geneva: World Health Organization.
2. UNAIDS. Report on the global HIV/AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS. July 2004.
3. UNICEF/WHO. Technical consultation: Improving access to appropriate paediatric ARV formulations. 3-4 November 2004. Geneva, Switzerland.
4. Menson EN, Walker AS, Sharland M, et al. for the Collaborative HIV Paediatric Study Steering Committee. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. Brit Med J 2006; 332:1183-1187.
5. Chokephaibulkit K, Plipat N, Cressey TR, et al. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS 2005; 19:1495-1499.
6. Corbett A, Hosseinipour M, Nyirenda J, et al. Pharmacokinetics between trade and generic liquid and split tablet formulations of lamivudine, stavudine and nevirapine in HIV infected Malawian children. 45th International Conference on Antimicrobial Agents and Chemotherapy. 16-19 December 2005, Washington, DC, USA. Poster 1106.
7. Ministry of Health, Malawi. (2003) Treatment of AIDS: Guidelines for the use of antiretroviral therapy in Malawi. 1st edn.
8. Chintu C, Bhat GJ, Walker AS, et al. for the CHAP trial team. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2005; 365:749-750.
9. WHO. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings, towards universal access: recommendations for a public health approach (2006 revision). February 2006. Geneva: World Health Organization.
10. Hollanders RMW, van Ewijk-Beneken Kolmer EWJ, Burger DM, Wuis EW, Koopmans PP, Hekster YA. Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chrom B Biomed Sci Appl 2000; 744:65-71.
11. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 1998; 17:407-429.
12. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Advance Data 2000; 314:1-27.
13. Vries-Sluijs TE, Dieleman JP, Arts D, et al. Low nevirapine plasma concentrations predict virological failure in an unsetected HIV-1-infected population. Clin Pharmacokinet 2003; 42:599-605.
14. Leth FV, Kappelhoff BS, Johnson D, et al; 2NN Study Group. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral activity. AIDS Res Hum Retroviruses 2006; 22:232-239.
15. Veldkamp AI, Weverling GJ, Lange JMA, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15:1089-1095.
16. Royston P, Altman DG. Regression Using Fractional Polynomials of Continuous Covariates: Parsimonious Parametric Modelling. Appl Stat 1994; 43:429-467.
17. Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM, on behalf of the PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004; 5:61-86.
18. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998; 18:83-97.
19. Zhou S, Yung Chan S, Cher Goh B, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005; 44:279-304.
20. Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996; 174:713-721.
21. Gonzalez de Requena D, Bonora S, Garazzino S, et al. Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother 2005; 49:3966-3969.
22. Bergshoeff A, Burger D, Verweij C, et al. on behalf of the PENTA 13 study group. Pharmacokinetics of once versus twice daily lamivudine and abacavir. Simplification of combination treatment in HIV-1 infected children (Penta 13). Antivir Ther 2005; 10:239-246.
23. Gibb DM. Overview of key obstacles and issues for consideration in relation to antiretroviral drugs for children in resource-poor settings. Invited discussion paper. UNICEF/WHO Technical Consultation: improving access to appropriate paediatric antiretroviral formulations. 3-4 November 2004. Geneva, Switzerland.
24. Mackie NE, Fidler S, Tamm N, et al. Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. HIV Med 2004; 5:180-184.
25. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-2400.
26. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15:1-5.
27. Verweel G, Sharland M, Lyall H, et al. Nevirapine use in HIV-1-infected children. AIDS 2003; 17:1639-1647.